Amarin Dirección
Dirección controles de criterios 1/4
El CEO de Amarin es Aaron Berg , nombrado en Jun 2024, tiene una permanencia de 1.92 años. compensación anual total es $3.54M, compuesta por 20.5% salario y 79.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.6% de las acciones de la empresa, por valor de $1.83M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 3.3 años, respectivamente.
Información clave
Aaron Berg
Chief Executive Officer (CEO)
US$3.5m
Compensación total
| Porcentaje del salario del CEO | 20.50% |
| Permanencia del CEO | 1.9yrs |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 1.9yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 21
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Analysts have lifted their price target on Amarin stock by $0.50 to $12.50, citing updated assumptions around slightly lower expected revenue declines, a higher projected profit margin, a modestly reduced discount rate, and a lower future P/E multiple as the key drivers of the change. Analyst Commentary Recent commentary around Amarin’s updated price target highlights a mix of optimism on execution and ongoing caution on longer term growth and valuation risk.Actualización de narrativa • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Actualización de narrativa • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Actualización de narrativa • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.Actualización de narrativa • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.Actualización de narrativa • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.Actualización de narrativa • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.Actualización de narrativa • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.Actualización de narrativa • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).Artículo de análisis • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Actualización de narrativa • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.Actualización de narrativa • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.Artículo de análisis • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...Artículo de análisis • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...Artículo de análisis • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
Nueva narrativa • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.Artículo de análisis • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...Artículo de análisis • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...Artículo de análisis • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...Artículo de análisis • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking AlphaArtículo de análisis • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking AlphaArtículo de análisis • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$34m |
| Dec 31 2025 | US$4m | US$726k | -US$39m |
| Sep 30 2025 | n/a | n/a | -US$86m |
| Jun 30 2025 | n/a | n/a | -US$104m |
| Mar 31 2025 | n/a | n/a | -US$88m |
| Dec 31 2024 | US$3m | US$663k | -US$82m |
| Sep 30 2024 | n/a | n/a | -US$39m |
| Jun 30 2024 | n/a | n/a | -US$34m |
| Mar 31 2024 | n/a | n/a | -US$53m |
| Dec 31 2023 | US$2m | US$622k | -US$59m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$2m | US$567k | -US$106m |
| Sep 30 2022 | n/a | n/a | -US$92m |
| Jun 30 2022 | n/a | n/a | -US$100m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$3m | US$505k | US$8m |
| Sep 30 2021 | n/a | n/a | -US$2m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$927k |
| Dec 31 2020 | US$4m | US$458k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$19m |
| Dec 31 2019 | US$3m | US$438k | -US$23m |
Compensación vs. Mercado: La compensación total de Aaron($USD3.54M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.60M).
Compensación vs. Ingresos: La compensación de Aaron ha aumentado mientras la empresa no es rentable.
CEO
Aaron Berg (62 yo)
1.9yrs
Permanencia
US$3,540,366
Compensación
Mr. Aaron D. Berg is President & Chief Executive Officer at Amarin Corporation plc since June 2024 and serves as its Director. He had been Executive VP & President of U.S. at Amarin Corporation plc until J...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 1.9yrs | US$3.54m | 0.60% $ 1.8m | |
| Senior VP & CFO | 1.6yrs | US$1.04m | 0.047% $ 142.5k | |
| Executive VP & Chief Operating Officer | less than a year | US$1.62m | 0.056% $ 168.7k | |
| Executive VP | 10.3yrs | US$1.92m | 0.37% $ 1.1m | |
| Executive VP | 2.5yrs | US$1.36m | 0.010% $ 31.7k | |
| Senior Vice President of Corporate Development | no data | sin datos | sin datos |
1.9yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AMRN no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | no data | US$3.54m | 0.60% $ 1.8m | |
| Chairman of Scientific Advisory Board | 20yrs | US$39.00k | sin datos | |
| Member of Scientific Advisory Board | 20yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 20yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 20yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 3.3yrs | US$67.53k | 0.035% $ 106.7k | |
| Independent Non-Executive Chairperson of the Board | 3.3yrs | US$73.58k | 0.0040% $ 12.1k | |
| Independent Non-Executive Director | 3.3yrs | US$68.84k | 0.0040% $ 12.1k | |
| Independent Non-Executive Director | 3.3yrs | US$71.90k | 0.0040% $ 12.1k | |
| Independent Non-Employee Director | 1.1yrs | US$31.19k | 2.31% $ 7.0m | |
| Independent Non-Executive Director | 3.3yrs | US$63.09k | 0.0040% $ 12.1k |
3.3yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de AMRN se considera experimentada (3.3 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/29 11:16 |
| Precio de las acciones al final del día | 2026/05/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Amarin Corporation plc está cubierta por 19 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |